COMMUNIQUÉS West-GlobeNewswire

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
30/09/2025
Disc is seeking accelerated approval and priority review of its NDA submission FDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- [...]
Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
30/09/2025
Previously Unpublished Data Confirms Vivos DNA Devices Offer a Safe and Effective Alternative Treatment for Children with ADHD and Obstructive Sleep Apnea LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos [...]
Vivex Biologics Treats First Patient in its Restore Trial Evaluating VIA Disc NP™ for Patients with Degenerative Disc Disease
30/09/2025
MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced that it has treated the first patient in its Restore U.S. clinical trial evaluating [...]
September 2025 Letter to Shareholders
30/09/2025
VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. (“CytoDyn” or the “Company”), I am pleased to share the progress we have made in [...]
La première édition de la Course vers la Percée de la Fondation du CUSM remporte un franc succès lors du Marathon de Montréal
30/09/2025
MONTRÉAL, 30 sept. 2025 (GLOBE NEWSWIRE) -- La Fondation du CUSM est fière d’avoir organisé sa première Course vers la Percée lors du Marathon de Montréal. Cet événement a réuni 22 équipes et près de 200 coureurs [...]
The MUHC Foundation’s Inaugural Breakthrough Run Wins Big at the Montreal Marathon
30/09/2025
MONTREAL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The MUHC Foundation proudly hosted its inaugural Breakthrough Run at the Montreal Marathon, bringing together 22 teams and almost 200 dedicated runners, including health care [...]
Coloplast A/S - Financial Calendar 2025-26
30/09/2025
Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://www.coloplast.com/investor-relations/events-calendar/ Kind regards, Investor Relations Coloplast A/S Tel [...]
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
30/09/2025
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence of gastric cancer [...]
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
30/09/2025
The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world’s leading surgical conferences PETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: [...]
24/7 Market News: Sportswear and Smart Textiles are likely Key Spider Silk Target Markets for Kraig Labs
30/09/2025
DENVER, Sept. 30, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, highlights the opportunity for recombinant spider [...]
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
30/09/2025
Watch the "What This Means" video here Featuring Company’s second-generation T-Cell Engager program and advantages over first-generation Company’s T-Cell Engager program has made improvements in manufacturability, [...]
Parexel Announces AI Partnership with Weave Bio to Accelerate Regulatory Submission Processes
30/09/2025
Collaboration leverages Parexel's proven regulatory expertise and Weave Bio's AI-native platform, aims to speed up market introduction of new therapies RALEIGH, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Parexel, a [...]
Thousands of State of Georgia employees walk 880 million steps to benefit Title I schools
30/09/2025
State Health Benefit Plan members come together to help young Georgians in their communities while improving their personal health ‘Jump Shot for Health’ awards winning schools new sports equipment and renovated [...]
Acentra Health’s Dr. Ryan Bosch Named a 2025 Innovator in Health Care by Washington Business Journal
30/09/2025
Award honors Dr. Bosch as one of Greater Washington’s top leaders for delivering the innovation, data strategy, and clinical insight needed to meet healthcare’s biggest challenges MCLEAN, Va., Sept. 30, 2025 (GLOBE [...]
Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.
30/09/2025
Strategic Acquisition Bolsters AI-Driven Healthcare Innovation, Positioning Fifty 1 Labs as a Leader in Clinical Data Analytics VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs Inc [...]
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
30/09/2025
GERMANTOWN, MD and ALTRINCHAM, UK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are [...]
HNL Lab Medicine Introduces Self-Collected HPV Test to Increase Privacy and Access
30/09/2025
ALLENTOWN, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- HNL Lab Medicine is pleased to offer a new self-collected HPV test that enhances patient privacy and convenience. This test detects 14 high-risk strains of Human [...]
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
30/09/2025
Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo [...]
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
30/09/2025
STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]

Pages